Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Molecular mechanisms of convergent color pattern evolution.

Kratochwil CF.

Zoology (Jena). 2019 Jun;134:66-68. doi: 10.1016/j.zool.2019.04.004. Epub 2019 Apr 14.

PMID:
31146908
2.

Genome of the Malawi golden cichlid fish (Melanochromis auratus) reveals exon loss of oca2 in an amelanistic morph.

Kratochwil CF, Urban S, Meyer A.

Pigment Cell Melanoma Res. 2019 May 27. doi: 10.1111/pcmr.12799. [Epub ahead of print]

PMID:
31131985
3.

FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis.

Giesel FL, Heussel CP, Lindner T, Röhrich M, Rathke H, Kauczor HU, Debus J, Haberkorn U, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2019 May 22. doi: 10.1007/s00259-019-04346-z. [Epub ahead of print] No abstract available.

PMID:
31119317
4.

DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay.

Schmeiser HH, Muehlbauer KR, Mier W, Baranski AC, Neels O, Dimitrakopoulou-Strauss A, Schmezer P, Kratochwil C, Bruchertseifer F, Morgenstern A, Kopka K.

Mutagenesis. 2019 May 20. pii: gez007. doi: 10.1093/mutage/gez007. [Epub ahead of print]

PMID:
31107537
5.

PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY.

Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel F, Van de Wiele C, Morgenstern A.

J Nucl Med. 2019 May 17. pii: jnumed.119.229229. doi: 10.2967/jnumed.119.229229. [Epub ahead of print]

PMID:
31101746
6.

68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL.

J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.

PMID:
30954939
7.

Development of novel FAP-targeted radiotracers with improved tumor retention.

Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, Debus J, Marme F, Jaeger D, Mier W, Haberkorn U.

J Nucl Med. 2019 Mar 8. pii: jnumed.118.224469. doi: 10.2967/jnumed.118.224469. [Epub ahead of print]

PMID:
30850501
8.

Fragile DNA contributes to repeated evolution.

Kratochwil CF, Meyer A.

Genome Biol. 2019 Feb 21;20(1):39. doi: 10.1186/s13059-019-1655-x.

9.

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.

Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C.

Oncotarget. 2019 Jan 1;10(1):17-29. doi: 10.18632/oncotarget.26523. eCollection 2019 Jan 1.

10.

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?

Dos Santos JC, Schäfer M, Bauder-Wüst U, Lehnert W, Leotta K, Morgenstern A, Kopka K, Haberkorn U, Mier W, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1081-1091. doi: 10.1007/s00259-018-4220-z. Epub 2019 Jan 3.

11.

68Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging.

Yang J, Xu J, Gonzalez R, Lindner T, Kratochwil C, Miao Y.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaau4445. doi: 10.1126/scitranslmed.aau4445.

PMID:
30404861
12.

Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617.

Rathke H, Flechsig P, Mier W, Bronzel M, Mavriopoulou E, Hohenfellner M, Giesel FL, Haberkorn U, Kratochwil C.

J Nucl Med. 2019 Jun;60(6):806-811. doi: 10.2967/jnumed.118.218917. Epub 2018 Nov 2.

PMID:
30389816
13.

Agouti-related peptide 2 facilitates convergent evolution of stripe patterns across cichlid fish radiations.

Kratochwil CF, Liang Y, Gerwin J, Woltering JM, Urban S, Henning F, Machado-Schiaffino G, Hulsey CD, Meyer A.

Science. 2018 Oct 26;362(6413):457-460. doi: 10.1126/science.aao6809.

PMID:
30361373
14.

Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.

Targeted Alpha Therapy Working Group, Parker C, Lewington V, Shore N, Kratochwil C, Levy M, Lindén O, Noordzij W, Park J, Saad F.

JAMA Oncol. 2018 Dec 1;4(12):1765-1772. doi: 10.1001/jamaoncol.2018.4044.

PMID:
30326033
15.

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT.

Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, Morgenstern A, Hein M, Plinkert P, Haberkorn U, Bulut OC.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):139-147. doi: 10.1007/s00259-018-4135-8. Epub 2018 Aug 27.

PMID:
30151743
16.

Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia.

Bulut OC, Haufe S, Hohenberger R, Hein M, Kratochwil C, Rathke H, Plinkert PK, Baumann I, Holland-Letz T, Haberkorn U, Flechsig P.

Nuklearmedizin. 2018 Aug;57(4):160-167. doi: 10.3413/Nukmed-0964-18-03. Epub 2018 Aug 20.

PMID:
30125928
17.

68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U.

J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2.

18.

Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer V, Kopka K, Eiber M.

J Nucl Med. 2019 Mar;60(3):362-368. doi: 10.2967/jnumed.118.212233. Epub 2018 Jul 24.

19.

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2045-2054. doi: 10.1007/s00259-018-4079-z. Epub 2018 Jul 7.

20.

68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.

Koerber SA, Will L, Kratochwil C, Haefner MF, Rathke H, Kremer C, Merkle J, Herfarth K, Kopka K, Choyke PL, Holland-Letz T, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2018 Jul 5. pii: jnumed.118.211086. doi: 10.2967/jnumed.118.211086. [Epub ahead of print]

PMID:
29976697
21.

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.

Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F.

Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524. Review.

22.

Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.

Flechsig P, Rastgoo R, Kratochwil C, Martin O, Holland-Letz T, Harms A, Kauczor HU, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2018 Dec;20(6):1044-1052. doi: 10.1007/s11307-018-1196-9.

PMID:
29679299
23.

A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts.

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jäger D, Giesel F, Kratochwil C, Barthe P, Roumestand C, Haberkorn U.

J Nucl Med. 2018 Sep;59(9):1423-1429. doi: 10.2967/jnumed.118.210435. Epub 2018 Apr 6.

24.

Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, Jäger D, Mier W, Haberkorn U.

J Nucl Med. 2018 Sep;59(9):1415-1422. doi: 10.2967/jnumed.118.210443. Epub 2018 Apr 6.

PMID:
29626119
25.

Early developmental and allometric patterns in the electric yellow cichlid Labidochromis caeruleus.

Saemi-Komsari M, Mousavi-Sabet H, Kratochwil CF, Sattari M, Eagderi S, Meyer A.

J Fish Biol. 2018 Jun;92(6):1888-1901. doi: 10.1111/jfb.13627. Epub 2018 Apr 26.

PMID:
29624691
26.

Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy.

Stade F, Dittmar JO, Jäkel O, Kratochwil C, Haberkorn U, Debus J, Combs SE.

Radiat Oncol. 2018 Apr 2;13(1):58. doi: 10.1186/s13014-018-1008-z.

27.

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma - Is PSMA-PET-CT a helpful tool in radiation oncology?

König L, Hauswald H, Flechtenmacher C, Heller M, Debus J, Haberkorn U, Kratochwil C, Giesel F.

Clin Transl Radiat Oncol. 2017 Nov 14;7:79-82. doi: 10.1016/j.ctro.2017.10.003. eCollection 2017 Dec.

28.

Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC, Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.

29.

Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.

Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Sep;59(9):1373-1379. doi: 10.2967/jnumed.117.200220. Epub 2018 Jan 25.

PMID:
29371410
30.

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A.

J Nucl Med. 2018 May;59(5):795-802. doi: 10.2967/jnumed.117.203539. Epub 2018 Jan 11.

31.

[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty.

Giesel FL, Will L, Paddubny K, Kremer C, Rathke H, Radtke JP, Kopka K, Haufe S, Haberkorn U, Kratochwil C.

Clin Genitourin Cancer. 2018 Apr;16(2):111-113. doi: 10.1016/j.clgc.2017.11.008. Epub 2017 Dec 6. No abstract available.

32.

Role of CT Density in PET/CT-Based Assessment of Lymphoma.

Flechsig P, Walker C, Kratochwil C, König L, Iagura A, Moltz J, Holland-Letz T, Kauczor HU, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2018 Aug;20(4):641-649. doi: 10.1007/s11307-017-1155-x.

PMID:
29270848
33.

Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.

Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M.

J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21.

PMID:
29269569
34.

Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients.

Will L, Giesel FL, Freitag MT, Berger AK, Mier W, Kopka K, Koerber SA, Rathke H, Kremer C, Kratochwil C, Kauczor HU, Haberkorn U, Weber TF.

Cancer Imaging. 2017 Dec 20;17(1):30. doi: 10.1186/s40644-017-0132-6.

36.

Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy.

Paddubny K, Freitag MT, Kratochwil C, Koerber S, Radtke JP, Sakovich R, Kopka K, Giesel FL.

Clin Genitourin Cancer. 2018 Apr;16(2):103-105. doi: 10.1016/j.clgc.2017.09.014. Epub 2017 Oct 5. No abstract available.

37.

First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas.

Dittmar JO, Kratochwil C, Dittmar A, Welzel T, Habermehl D, Rieken S, Giesel FL, Haberkorn U, Debus J, Combs SE.

Radiat Oncol. 2017 Nov 6;12(1):169. doi: 10.1186/s13014-017-0913-x.

38.

Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.

Freitag MT, Kesch C, Cardinale J, Flechsig P, Floca R, Eiber M, Bonekamp D, Radtke JP, Kratochwil C, Kopka K, Hohenfellner M, Stenzinger A, Schlemmer HP, Haberkorn U, Giesel F.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):340-347. doi: 10.1007/s00259-017-3854-6. Epub 2017 Oct 16.

PMID:
29038888
39.

Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.

Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, Haberkorn U, Giesel FL.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):31-37. doi: 10.1007/s00259-017-3817-y. Epub 2017 Sep 11.

40.

Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq.

Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Mar;59(3):459-465. doi: 10.2967/jnumed.117.194209. Epub 2017 Aug 10.

41.

177Lu-PSMA Radioligand Therapy for Prostate Cancer.

Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M.

J Nucl Med. 2017 Aug;58(8):1196-1200. doi: 10.2967/jnumed.117.191023. Epub 2017 Jun 29. Review. Erratum in: J Nucl Med. 2018 Feb;59(2):346.

42.

Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1781. doi: 10.1007/s00259-017-3763-8. No abstract available.

PMID:
28656360
43.

68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.

J Nucl Med. 2017 Dec;58(12):1949-1955. doi: 10.2967/jnumed.116.185033. Epub 2017 Jun 21.

44.

68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters.

Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, Mier W, Iagaru AH, Herfarth K, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2017 Dec;58(12):1943-1948. doi: 10.2967/jnumed.117.190314. Epub 2017 Jun 15.

45.

The Long Journey of Pontine Nuclei Neurons: From Rhombic Lip to Cortico-Ponto-Cerebellar Circuitry.

Kratochwil CF, Maheshwari U, Rijli FM.

Front Neural Circuits. 2017 May 17;11:33. doi: 10.3389/fncir.2017.00033. eCollection 2017. Review.

46.

[Significance and Value of PSMA Ligands in Prostate Cancer].

Gasch C, Körber S, Kremer C, Eiber M, Kratochwil C, Haberkorn U, Hohenfellner M, Hadaschik B, Giesel FL.

Aktuelle Urol. 2017 Apr;48(2):140-147. doi: 10.1055/s-0043-100269. Epub 2017 May 16. German.

PMID:
28511220
47.

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. doi: 10.1007/s00259-017-3711-7. Epub 2017 May 12. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1781.

48.

Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.

Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL.

J Nucl Med. 2017 Nov;58(11):1805-1810. doi: 10.2967/jnumed.116.189233. Epub 2017 May 4. Erratum in: J Nucl Med. 2019 Apr;60(4):554.

49.

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.

Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A.

J Nucl Med. 2017 Oct;58(10):1624-1631. doi: 10.2967/jnumed.117.191395. Epub 2017 Apr 13.

50.

The Future of Radioligand Therapy: α, β, or Both?

Haberkorn U, Giesel F, Morgenstern A, Kratochwil C.

J Nucl Med. 2017 Jul;58(7):1017-1018. doi: 10.2967/jnumed.117.190124. Epub 2017 Apr 13. No abstract available.

Supplemental Content

Loading ...
Support Center